Somewhat Positive Media Coverage Somewhat Unlikely to Affect Sunesis Pharmaceuticals (NASDAQ:SNSS) Share Price
Headlines about Sunesis Pharmaceuticals (NASDAQ:SNSS) have trended somewhat positive on Monday, according to Accern Sentiment. The research firm identifies negative and positive press coverage by monitoring more than twenty million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. Sunesis Pharmaceuticals earned a daily sentiment score of 0.22 on Accern’s scale. Accern also assigned headlines about the biopharmaceutical company an impact score of 47.1143691995693 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the next several days.
These are some of the news headlines that may have effected Accern’s scoring:
- Small Cap Concentration on Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS) – FLBC News (flbcnews.com)
- Investor Update: Focusing in on Shares of Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS) – Sparta Review (spartareview.com)
Sunesis Pharmaceuticals (NASDAQ SNSS) traded up 3.88% during midday trading on Monday, hitting $2.41. The stock had a trading volume of 62,831 shares. Sunesis Pharmaceuticals has a 1-year low of $2.19 and a 1-year high of $6.30. The company’s market capitalization is $56.67 million. The stock’s 50-day moving average is $2.62 and its 200-day moving average is $3.42.
Sunesis Pharmaceuticals (NASDAQ:SNSS) last released its quarterly earnings results on Thursday, July 27th. The biopharmaceutical company reported ($0.41) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.76) by $0.35. During the same period in the previous year, the business posted ($0.12) earnings per share. Equities research analysts forecast that Sunesis Pharmaceuticals will post ($1.61) EPS for the current year.
A number of research firms have recently weighed in on SNSS. Zacks Investment Research raised Sunesis Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Wednesday, August 2nd. Cantor Fitzgerald reissued a “hold” rating and issued a $3.00 target price on shares of Sunesis Pharmaceuticals in a research note on Thursday, July 27th.
Sunesis Pharmaceuticals Company Profile
Sunesis Pharmaceuticals, Inc is a biopharmaceutical company. The Company focuses on the development and commercialization of its pipeline of oncology therapeutics for the treatment of solid and hematologic cancers. The Company offers QINPREZO (vosaroxin), which is a product candidate for the treatment of acute myeloid leukemia (AML).
Receive News & Stock Ratings for Sunesis Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sunesis Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.